Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29599619 | 0.82 | NPC1 (0.51) | NPC1RAB9ALMNATAAR1FOLH1 | |
| SCHEMBL16228011 | 0.82 | MMP1 (0.52) | — | |
| SCHEMBL16228013 | 0.82 | MMP1 (0.52) | — | |
| SCHEMBL11888384 | 0.81 | NPY1R (0.41) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL4462033 | 0.79 | NPC1 (0.67) | NPC1RAB9ALMNATAAR1ALDH1A1 | |
| SCHEMBL8420771 | 0.79 | NPC1 (0.67) | NPC1RAB9ALMNATAAR1ALDH1A1 | |
| SCHEMBL6679690 | 0.79 | NPC1 (0.67) | NPC1RAB9ALMNATAAR1ALDH1A1 | |
| SCHEMBL14637585 | 0.78 | CTSK (0.55) | PTPN1 | |
| SCHEMBL10135741 | 0.78 | CTSK (0.55) | PTPN1 | |
| SCHEMBL16288647 | 0.78 | NPY1R (0.49) | EGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190880-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | BLUE OWL CAPITAL CORPORATION, AS NEW AGENT | 2012-07-26 | — | — | US | disclosed |
| WO-2010148305-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | CAMBREX CHARLES CITY, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190880-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | PNMT, COMT, DDT | NPC1 3576/4885RAB9A 1955/4885PTPN2 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.